A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin

NCT02794792 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

268

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Ipragliflozin L-proline
DRUG: Metformin
DRUG: Placebo

Sponsor

Astellas Pharma Europe B.V.